Orthofix (OFIX) reported preliminary 4Q17 revenue of US $116.9MM, +7.7% vs. 4Q16, and 2017 revenue of $433.8MM, +5.9% vs. 2016. Full-year revenue exceeds the $431.0MM high end of guidance that was revised in 3Q17.
Priorities for 2018 include additional sales representation in under-served markets, as well as investments in R&D, new products and value-added servcies (e.g. JuniOrtho™ pediatric care support tools). Leadership noted that OFIX is well-positioned to acquire products, technologies and companies.
For 2018, the company published net sales guidance in a range of $450.0MM to $455.0MM.
Due to the lowered U.S. corporate tax rate, OFIX expects a one-time tax change of $8.0MM to $12.0MM in 4Q17.
An update on the company’s comments on the revised tax rate will be reported with final financial results in late February 2018.
Orthofix (OFIX) reported preliminary 4Q17 revenue of US $116.9MM, +7.7% vs. 4Q16, and 2017 revenue of $433.8MM, +5.9% vs. 2016. Full-year revenue exceeds the $431.0MM high end of guidance that was revised in 3Q17.
Priorities for 2018 include additional sales representation in under-served markets, as well as investments in R&D, new...
Orthofix (OFIX) reported preliminary 4Q17 revenue of US $116.9MM, +7.7% vs. 4Q16, and 2017 revenue of $433.8MM, +5.9% vs. 2016. Full-year revenue exceeds the $431.0MM high end of guidance that was revised in 3Q17.
Priorities for 2018 include additional sales representation in under-served markets, as well as investments in R&D, new products and value-added servcies (e.g. JuniOrtho™ pediatric care support tools). Leadership noted that OFIX is well-positioned to acquire products, technologies and companies.
For 2018, the company published net sales guidance in a range of $450.0MM to $455.0MM.
Due to the lowered U.S. corporate tax rate, OFIX expects a one-time tax change of $8.0MM to $12.0MM in 4Q17.
An update on the company’s comments on the revised tax rate will be reported with final financial results in late February 2018.
Copy to clipboard 
